Meta-analysis of Adjuvant Therapy Trials for Pancreatic Cancer
Author Information
Author(s): Stocken D D, Büchler M W, Dervenis C, Bassi C, Jeekel H, Klinkenbijl J H G, Bakkevold K E, Takada T, Amano H, Neoptolemos J P
Primary Institution: Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK
Hypothesis
The study investigates the roles of adjuvant chemoradiation and adjuvant chemotherapy on survival in potentially curative resected pancreatic cancer.
Conclusion
Chemotherapy is an effective adjuvant treatment for pancreatic cancer, while chemoradiation does not show significant benefits.
Supporting Evidence
- Chemotherapy showed a 25% significant reduction in the risk of death.
- Median survival was 19.0 months with chemotherapy compared to 13.5 months without.
- 2- and 5-year survival rates were higher with chemotherapy (38% and 19%) than without (28% and 12%).
- Chemoradiation did not show a significant difference in the risk of death.
- Median survival with chemoradiation was 15.8 months, similar to 15.2 months without.
Takeaway
This study looked at different treatments for pancreatic cancer after surgery and found that chemotherapy helps people live longer, but chemoradiation does not.
Methodology
The study is a meta-analysis of five randomized controlled trials, pooling individual patient data to assess treatment effects on survival.
Potential Biases
Potential biases may arise from the inclusion of trials with different treatment regimens and patient characteristics.
Limitations
The study may have limitations due to the heterogeneity of included trials and the varying patient populations.
Participant Demographics
Participants were predominantly male (58%) and aged over 60 years (55%), with varying resection margin statuses.
Statistical Information
P-Value
0.001
Confidence Interval
0.64, 0.90
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website